Pharming Group (PHAR) Set to Announce Quarterly Earnings on Thursday

Pharming Group (NASDAQ:PHAR) is scheduled to be issuing its quarterly earnings data before the market opens on Thursday, October 24th. Analysts expect the company to announce earnings of $0.01 per share for the quarter. Pharming Group has set its FY 2024 guidance at EPS.

Pharming Group (NASDAQ:PHAR) last posted its earnings results on Thursday, August 1st. The company reported ($0.01) earnings per share for the quarter. Pharming Group had a negative return on equity of 5.69% and a negative net margin of 4.65%. The business had revenue of $74.09 million during the quarter, compared to the consensus estimate of $71.95 million. During the same quarter last year, the firm earned $0.02 earnings per share. On average, analysts expect Pharming Group to post $0 EPS for the current fiscal year and $0 EPS for the next fiscal year.

Pharming Group Stock Performance

Pharming Group stock opened at $8.91 on Tuesday. The company’s 50-day moving average price is $7.94 and its 200-day moving average price is $8.59. Pharming Group has a twelve month low of $6.65 and a twelve month high of $13.20. The company has a quick ratio of 2.65, a current ratio of 3.39 and a debt-to-equity ratio of 0.40. The company has a market cap of $600.04 million, a PE ratio of -55.69 and a beta of 0.15.

Analyst Upgrades and Downgrades

Separately, HC Wainwright reaffirmed a “buy” rating and set a $37.00 price target on shares of Pharming Group in a research note on Thursday, October 10th.

About Pharming Group

Pharming Group N.V., a biopharmaceutical company, develops and commercializes protein replacement therapies and precision medicines for the treatment of rare diseases in the United States, Europe, and internationally. The company offers RUCONEST, a recombinant C1 esterase inhibitor for the treatment of acute attacks in adult and adolescent patients with acute hereditary angioedema (HAE); and Joenja (leniolisib), an oral small molecule PI3K? inhibitor for the treatment of activated phosphoinositide 3-kinase delta syndrome.